M S Pharma And Surgical

Secukinumab, branded as Cosentyx®, is a biologic, fully human monoclonal antibody injection used to treat various chronic autoimmune and inflammatory diseases. It is a targeted immune therapy that works by blocking the protein interleukin-17A (IL-17A) to reduce inflammation. Key Descriptions

• Drug Type: Biologic immunomodulator and IL-17A inhibitor.
• Mechanism of Action: Secukinumab specifically binds to the pro-inflammatory protein IL-17A, preventing it from interacting with receptors in the body. This action reduces inflammation and alleviates symptoms of the associated conditions.
• Uses (Indications): It is used to treat several conditions in both adult and some pediatric patients, including:
  • Moderate to severe plaque psoriasis (PsO)
  • Active psoriatic arthritis (PsA)
  • Active ankylosing spondylitis (AS)
  • Active non-radiographic axial spondyloarthritis (nr-axSpA)
  • Active enthesitis-related arthritis (ERA)
  • Moderate to severe hidradenitis suppurativa (HS)

a prescription combination of two antiviral medicines, sofosbuvir (400mg) and velpatasvir (100mg), used primarily for the treatment of chronic hepatitis C virus (HCV) infection. It is a pangenotypic (effective against all six main types of HCV) treatment option. Key Description Points

• Active Ingredients: Each tablet contains 400 mg of Sofosbuvir and 100 mg of Velpatasvir.
• Mechanism of Action: The components work by inhibiting specific viral proteins (NS5B polymerase and NS5A, respectively), which prevents the hepatitis C virus from replicating and spreading in the body.
• Uses: It is prescribed to treat chronic hepatitis C in adults and children aged 3 years and older, often with very high cure rates when the full course is completed.
• Administration: It is typically a once-daily single-tablet treatment taken with or without food, at the same time each day.
• Treatment Duration: The typical course of treatment is usually 12 or 24 weeks, depending on the specific HCV genotype and the patient's medical history.
• Manufacturer: It is a generic version of Gilead's brand Epclusa, manufactured and marketed by Natco Pharma Ltd. in India under a licensing agreement.